Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008630 | 0.88 | KDM4E (0.40) | ALDH1A1HPGDTSPO | |
| SCHEMBL3005861 | 0.88 | KDM4E (0.40) | ALDH1A1HPGDTSPO | |
| SCHEMBL13434165 | 0.80 | CCR5 (0.36) | — | |
| SCHEMBL3004130 | 0.80 | NR4A2 (0.32) | — | |
| SCHEMBL3011562 | 0.78 | FNTA (0.31) | — | |
| SCHEMBL3007154 | 0.75 | PKM (0.38) | POLBALDH1A1HPGD | |
| SCHEMBL3004699 | 0.75 | — | — | |
| SCHEMBL16363210 | 0.75 | OPRM1 (0.38) | — | |
| SCHEMBL2998942 | 0.75 | — | — | |
| SCHEMBL13437552 | 0.74 | TDP1 (0.33) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | POLB 4342/4885APEX1 1692/4885TDP1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.